DENTSPLY SIRONA Inc. (NASDAQ:XRAY – Get Rating) – William Blair lowered their Q2 2022 EPS estimates for shares of DENTSPLY SIRONA in a note issued to investors on Tuesday, May 10th. William Blair analyst J. Kreger now expects that the medical instruments supplier will post earnings of $0.62 per share for the quarter, down from their prior forecast of $0.65. William Blair has a “Market Perform” rating on the stock. William Blair also issued estimates for DENTSPLY SIRONA’s Q3 2022 earnings at $0.64 EPS, Q4 2022 earnings at $0.66 EPS, FY2022 earnings at $2.44 EPS, FY2023 earnings at $2.68 EPS, FY2024 earnings at $3.01 EPS, FY2025 earnings at $3.34 EPS and FY2026 earnings at $3.66 EPS.
Several other equities analysts have also recently issued reports on XRAY. Morgan Stanley reduced their price objective on DENTSPLY SIRONA from $62.00 to $52.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 20th. Piper Sandler restated a “neutral” rating and set a $46.00 price objective (down from $71.00) on shares of DENTSPLY SIRONA in a research note on Wednesday, April 20th. HC Wainwright reduced their price objective on DENTSPLY SIRONA from $58.00 to $48.00 and set a “hold” rating on the stock in a research note on Friday, April 22nd. Barrington Research reduced their price objective on DENTSPLY SIRONA from $53.00 to $51.00 in a research note on Wednesday. Finally, TheStreet cut DENTSPLY SIRONA from a “b-” rating to a “c+” rating in a research note on Friday, March 18th. Seven investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, DENTSPLY SIRONA presently has an average rating of “Hold” and an average price target of $52.89.
DENTSPLY SIRONA (NASDAQ:XRAY – Get Rating) last released its quarterly earnings results on Tuesday, May 10th. The medical instruments supplier reported $0.52 earnings per share for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.04). DENTSPLY SIRONA had a return on equity of 11.63% and a net margin of 8.81%. The company had revenue of $9.67 billion for the quarter, compared to analyst estimates of $982.05 million. During the same period in the previous year, the business posted $0.72 EPS. The firm’s quarterly revenue was up 841.1% compared to the same quarter last year.
The business also recently announced a quarterly dividend, which was paid on Friday, April 8th. Shareholders of record on Friday, March 25th were paid a $0.125 dividend. This represents a $0.50 dividend on an annualized basis and a yield of 1.31%. This is a boost from DENTSPLY SIRONA’s previous quarterly dividend of $0.11. The ex-dividend date of this dividend was Thursday, March 24th. DENTSPLY SIRONA’s dividend payout ratio (DPR) is presently 29.59%.
In other DENTSPLY SIRONA news, Director Eric Brandt sold 6,900 shares of the firm’s stock in a transaction on Tuesday, May 3rd. The stock was sold at an average price of $39.71, for a total value of $273,999.00. Following the sale, the director now directly owns 35,155 shares in the company, valued at $1,396,005.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.69% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of XRAY. First Trust Advisors LP increased its holdings in shares of DENTSPLY SIRONA by 203.9% during the first quarter. First Trust Advisors LP now owns 91,083 shares of the medical instruments supplier’s stock valued at $4,517,000 after purchasing an additional 61,111 shares during the period. Amundi Pioneer Asset Management Inc. increased its holdings in shares of DENTSPLY SIRONA by 39.9% during the first quarter. Amundi Pioneer Asset Management Inc. now owns 184,628 shares of the medical instruments supplier’s stock valued at $9,157,000 after purchasing an additional 52,645 shares during the period. Morgan Stanley increased its holdings in shares of DENTSPLY SIRONA by 16.1% during the second quarter. Morgan Stanley now owns 607,754 shares of the medical instruments supplier’s stock valued at $38,445,000 after purchasing an additional 84,088 shares during the period. Truist Financial Corp increased its holdings in shares of DENTSPLY SIRONA by 0.9% during the third quarter. Truist Financial Corp now owns 72,644 shares of the medical instruments supplier’s stock valued at $4,218,000 after purchasing an additional 640 shares during the period. Finally, Russell Investments Group Ltd. increased its holdings in shares of DENTSPLY SIRONA by 44.8% during the third quarter. Russell Investments Group Ltd. now owns 79,479 shares of the medical instruments supplier’s stock valued at $4,620,000 after purchasing an additional 24,587 shares during the period. 94.79% of the stock is currently owned by institutional investors.
About DENTSPLY SIRONA (Get Rating)
DENTSPLY SIRONA Inc designs, develops, manufactures, distributes, and sells various dental products and technologies for professional dental market worldwide. It offers dental equipment, including treatment centers, imaging equipment, motorized dental handpieces, and other instruments; imaging equipment; treatment centers comprising basic dentist chairs, sophisticated chair-based units with integrated diagnostic, hygiene and ergonomic functionalities, and specialist centers; and lab equipment, such as amalgamators, mixing machines, and porcelain furnaces.
- Get a free copy of the StockNews.com research report on DENTSPLY SIRONA (XRAY)
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.